Last reviewed · How we verify

NCT05458778

Detection of Urinary Human Chorionic Gonadotropin (hCG)

Status unknown Last updated 1 May 2023
What this trial tests

trial testing Daily test with urine by the product in Pregnancy Detection in 200 participants. Status unknown.

Timeline
29 June 2022
Primary endpoint
31 October 2023
31 October 2023

Quick facts

Lead sponsorQuanovate Tech Inc.
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date29 June 2022
Primary completion31 October 2023
Estimated completion31 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Quanovate Tech Inc.

Who can join

Adults 18 to 80, female only, with Pregnancy Detection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Mira Pregnancy Test is an over-the-counter urine hCG test intended for early detection of pregnancy. The test is indicated for use four days before the expected period. Throughout this study, volunteers with non-medical backgrounds were recruited to test hCG with urine samples using the Mira Pregnancy Test during the not pregnancy cycle or pregnancy cycle. To perform the study, a total number of more than 200 volunteers will be recruited to participate in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Quanovate Tech Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05458778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing